All In Biotech

Drug Trial Radar · NCT07653685

A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

71

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).

Conditions

  • Colorectal Cancer

Interventions

  • TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injectionDrug

    TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis.

  • TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)Drug

    TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 DoseTime frame: Baseline up to 21 days
  2. Adverse event (AE)Time frame: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
  3. Objective Response RateTime frame: Baseline up to 24 months

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Gansu Provincial Tumor Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • The First People's Hospital of Foshan

    Foshan, Guangdong, China · Not yet recruiting

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Zhuang Autonomous Region Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Qiqihar First Hospital

    Qiqihar, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The first affiliated hospital of Zhengzhou university

    Zhengzhou, Henan, China · Not yet recruiting

  • The Third People's Hospital of Zhengzhou

    Zhengzhou, Henan, China · Not yet recruiting

  • Jingzhou First People's Hospital

    Jingzhou, Hubei, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Provincial Cancer Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China · Recruiting

  • Jiangxi Provincal People's Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University Medical College

    Xi'an, Shaanxi, China · Not yet recruiting

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital of Air Force Medical University

    Xi’an, Shanxi, China · Not yet recruiting

  • The Second Affiliated Hospital of Air Force Medical University

    Xi’an, Shanxi, China · Not yet recruiting

  • Tianjin Union Medical Center

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Xinjiang Medical University Affiliated Tumor Hospital

    Ürümqi, Xinjiang, China · Not yet recruiting

  • Lishui Municipal Central Hospital

    Lishui, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.